REG - Oxford Biomedica PLC - Admission to Trading

Oxford BioMedicaAnnouncement

Thu 08:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260430:nRSd5792Ca&default-theme=true

RNS Number : 5792C  Oxford Biomedica PLC  30 April 2026

 

OXB

Admission to Trading

 

In accordance with the Financial Conduct Authority's Prospectus Rules:
Admission to Trading on a Regulated Market (PRM) sourcebook 1.6.4R, OXB
notifies the market that following shares have been admitted to trading
pursuant to their allotment under the OXB Long Term Incentive Plan (LTIP), OXB
Sharesave Scheme (SAYE), OXB Employee Share Option Scheme (ESOS) as follows:

 

 Issuer name:                                                                OXFORD BIOMEDICA PLC

 Issuer LEI:                                                                 213800S1GVQNXQ15K851

 Regulated market on which the shares have been admitted to trading:         Main Market for listed securities of the London Stock Exchange

 Name, type and ISIN of the shares:                                          Ordinary shares of 50p each

                                                                             GB00BDFBVT43
 Number of further shares admitted to trading covered by the notification:   40,801

 Total number of shares admitted to trading (including the new shares):      120,914,240

 Confirmation that the new shares are fungible with existing shares already  Confirmed
 admitted to trading:

 Date range covered by the notification:                                     04 March 2026 - 15 April 2026

 

-Ends-

 

Enquiries:

 

OXB:

 

Natalie Walter, Chief Legal Officer and Group Company Secretary

T: +44 (0) 1865 783 000 / E: cosec@oxb.com

 

About OXB

 

OXB (LSE: OXB) is a global quality and innovation-led contract development and
manufacturing organisation (CDMO) in cell and gene therapy with a mission to
enable its clients to deliver life changing therapies to patients around the
world.

 

One of the original pioneers in cell and gene therapy, OXB has 30 years of
experience in viral vectors; the driving force behind the majority of cell and
gene therapies. OXB collaborates with some of the world's most innovative
pharmaceutical and biotechnology companies, providing viral vector development
and manufacturing expertise in lentivirus, adeno-associated virus (AAV),
adenovirus and other viral vector types. OXB's world-class capabilities range
from early-stage development to commercialisation. These capabilities are
supported by robust quality-assurance systems, analytical methods and depth of
regulatory expertise.

 

OXB offers a vast number of technologies for viral vector manufacturing,
including a 4th generation lentiviral vector system (the TetraVecta™
system), a dual-plasmid system for AAV production, suspension and perfusion
process using process enhancers and stable producer and packaging cell lines.

 

OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It
has development and manufacturing facilities across Oxfordshire, UK, Lyon and
Strasbourg, France, Bedford MA, and Durham NC, US. Learn more at www.oxb.com
(http://www.oxb.com) and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica) and YouTube.
(https://www.youtube.com/oxfordbiomedica)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ADMIMMRTMTBJMMF



            Copyright 2019 Regulatory News Service, all rights reserved